More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

At one point, BMS said the facility would house 400 people. That was before Chairman and CEO Chris Boerner replaced Giovanni ...

2seventy bio worked with BMS on the development of BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel), used to treat ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...

After raising an impressive 1.2 billion euros in 2024, European venture capital firm Sofinnova Partners is topping up its ...